Skip to main content

Table 1 Characterization of samples by disease status, stage and BRAF or NRAS mutation

From: Detecting copy number status and uncovering subclonal markers in heterogeneous tumor biopsies

Sample_ID Normal/Nevus/Melanoma Stage BRAF status NRAS status
HFSC Normal Normal NA NA
Nbmel Normal Normal NA NA
YULOVY Melanoma I, primary WT Q61L
YUPLA Melanoma II WT WT
YUGOE Melanoma III WT WT
YUKIM Melanoma III WT Q61R
YUROL Melanoma III WT WT
YUPAO Melanoma III, acral WT WT
YUCAS Melanoma IV WT WT
YUCHER Melanoma IV WT Q61R
YUMAG Melanoma IV WT Q61R / WT
YUROB Melanoma IV WT WT
YUSIV Melanoma IV WT WT
YUTUR Melanoma IV WT WT
YUZOR Melanoma IV WT WT
YUWERA Melanoma IV, acral WT WT
YUHOIN Melanoma IV, primary WT WT
YUDOSO Melanoma llb, primary WT Q61K / WT
YUHEIK Melanoma primary WT WT
YUFULO Melanoma primary WT Q61L / WT
YUSTE Melanoma III V600E WT
YUCAL Melanoma IV V600E WT
YUSAC Melanoma IV V600E WT
YUGEN8 Melanoma IV V600E WT
YUCLIR Giant nevus Giant nevus V600E / WT WT
YUSIK Melanoma III+ V600E / WT WT
YUNIBO Melanoma IIb, primary V600K WT
YUKSI Melanoma IV V600K WT
YULAC Melanoma IV V600K WT
YUMAC Melanoma IV V600K WT
YURIF Melanoma IV V600K WT
YUSIT Melanoma IV V600K / WT WT
  1. Samples have been characterized by disease status, stage and BRAF or NRAS mutation.